Alpha Tau Medical Ltd. has released its third quarter 2026 financial results, showcasing significant advancements in its clinical trials and corporate strategy. The updates highlight the company's ongoing commitment to developing innovative cancer therapies, particularly its Alpha DaRT treatment for recurrent glioblastoma.

On November 19, 2026, Alpha Tau Medical Ltd. (NASDAQ/TASE: DRTS, DRTSW) announced its third quarter financial results and provided a corporate update. The report is significant as it outlines the company's progress in clinical trials, particularly in the treatment of recurrent glioblastoma and pancreatic cancer.

Background

Alpha Tau Medical Ltd. is a company focused on developing advanced cancer therapies, specifically through its innovative alpha-radiation treatment, Alpha DaRT. The company operates under the SIC code 3841, which pertains to Surgical & Medical Instruments & Apparatus. Alpha Tau is listed on both the Nasdaq and the Tel Aviv Stock Exchange, reflecting its growing international presence.

What the Filing Says

The filing indicates that Alpha Tau has made substantial progress in its clinical trials. Notably, interim results from the U.S. REGAIN trial for recurrent glioblastoma show that all eight treated patients are alive, with a 100% objective response rate. The company has also received FDA approval to expand the REGAIN trial from 10 to 20 patients, which could support market submission requirements for Alpha DaRT.

Additionally, the company has completed patient enrollment in its multicenter IMPACT pilot study for pancreatic cancer, with 48 patients enrolled across multiple clinical centers in the U.S., Canada, and Israel. Alpha Tau's CEO, Uzi Sofer, expressed optimism about the trial results, stating, "Alpha Tau has tremendous momentum right now, and the new fantastic interim data from our REGAIN trial in recurrent glioblastoma showcase the true power of Alpha DaRT."

Impact

This update may significantly affect patients suffering from recurrent glioblastoma and pancreatic cancer, as Alpha Tau's advancements could lead to improved treatment options. The company's strong financial position, with a cash balance of $99.8 million, provides a solid foundation for continued clinical advancements and commercial preparations.

What's Next

Looking ahead, Alpha Tau is targeting the completion of its Hudson, New Hampshire plant for clinical trial supply by the end of 2026. The company anticipates meaningful additional data from multiple trials in the coming months, including top-line data from its pivotal ReSTART trial in recurrent cutaneous squamous cell carcinoma (cSCC) and initial data from the IMPACT trial.

As Alpha Tau Medical Ltd. continues to progress in its clinical trials and expand its manufacturing capabilities, the company is well-positioned to make a significant impact in the surgical and medical instruments industry.